NEW YORK, June 29 (newratings.com) - Analysts at RBC Capital Markets maintain their "sector perform" rating on ISTA Pharmaceuticals (ISTA) . The target price has been raised from $3 to $5.
In a research note published this morning, the analysts mention that an FDA panel has voted 7-0 in favour of approving Bepreve. The FDA approval reduces some risk related to the approval of Bepreve, the analysts say. ISTA Pharmaceuticals is likely to launch the drug by in January 2010, RBC Capital Markets adds. The company’s share price has, however, appreciated significantly in recent weeks.
$4.55 (06/29/09)
